Grufity logo
Grufity logo
VIRX

VIRX - Viracta Therapeutics, Inc. Stock Price, Fair Value and News

$0.01 
Market Closed as of 30 Dec 2025, 04:00 pm ET

Price Targets

VIRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VIRX Price Action

Trailing 12 Months

-95.8%

VIRX RSI Chart

VIRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VIRX Valuation

Market Cap

397.4K

Price/Earnings (Trailing)

-0.01

Price/Sales (Trailing)

0.19

EV/EBITDA

-0.23

Price/Free Cashflow

-0.01

VIRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

VIRX Fundamentals

VIRX Revenue

VIRX Earnings

VIRX Profitability

Free Cashflow Yield

-8.8K%

VIRX Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
20243.1M2.6M2.1M-
20232.0M2.9M3.2M3.3M
202242.0K80.0K544.0K1.2M
202114.0K22.0K31.0K38.0K
202058.0K54.6K51.3K48.0K
2019---61.3K
2018237.0K237.0K237.0K237.0K
20172.6M2.0M1.3M669.0K
20162.8M2.6M2.5M2.5M
20154.6M3.5M3.3M3.1M
20148.0M8.0M6.8M5.7M
20135.7M6.2M8.0M8.0M
2012-2.5M2.8M3.8M
20114.5M4.6M4.8M5.0M
2010-3.9M4.1M4.3M
2009---3.8M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Viracta Therapeutics, Inc.

VIRX
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor; and VRx-510, a preclinical-stage PDK-1 inhibitor. The company was formerly known as Sunesis Pharmaceuticals, Inc. and changed its name to Viracta Therapeutics, Inc. in February 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
 CEO
 WEBSITEviracta.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES41

Viracta Therapeutics, Inc. Frequently Asked Questions

VIRX is the stock ticker symbol of Viracta Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Dec 30 2025, market cap of Viracta Therapeutics, Inc. is 397.44 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Tue Dec 30 2025, VIRX's PE ratio (Price to Earnings) is -0.01 and Price to Sales (PS) ratio is 0.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VIRX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Viracta Therapeutics, Inc. has provided -0.629 (multiply by 100 for percentage) rate of return.